News related to Zolinza (Vorinostat) and/or conditions it is approved for
Immune Therapy Can Protect Against Or Treat Later Lymphoma
Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today [2009.11.03]
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.
Immunotherapy Demonstrates Long-Term Success In Treating Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.31]
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative Grants
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.30]
The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.
Lymphoma Patients Benefit From Exercise
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.28]
A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.
Pixantrone Produces High Rates Of Complete Remission In Multiple Relapsed And Refractory Indolent And Aggressive Non-Hodgkin's Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.23]
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.
Millennium Initiates Phase II Trial For Diffuse Large B-Cell Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.22]
Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.
Folotyn Approved for Aggressive Type of Non-Hodgkin's Lymphoma
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2009.09.28]
Title: Folotyn Approved for Aggressive Type of Non-Hodgkin's Lymphoma
Category: Health News
Created: 9/25/2009 12:10:00 PM
Last Editorial Review: 9/28/2009
Non-Hodgkins Lymphomas
Source: MedicineNet Biological Therapy Specialty [2009.08.14]
Title: Non-Hodgkins Lymphomas
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 8/14/2009
Immune-Based Lymphoma Treatment Shows Promise
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2009.06.01]
Title: Immune-Based Lymphoma Treatment Shows Promise
Category: Health News
Created: 6/1/2009 7:00:00 AM
Last Editorial Review: 6/1/2009
Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Source: MedicineNet Hodgkins Disease Specialty [2008.12.10]
Title: Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Category: Health News
Created: 12/10/2008 2:00:00 AM
Last Editorial Review: 12/10/2008
Breakthrough test clearly distinguishes Burkitt lymphoma from DLBCL
Source: The Doctors Lounge - Oncology
A gene expression signature clearly distinguishes Burkitt lymphoma from DLBCL, a critical distinction in diagnosis.
StemEx(R) Noted As A Reliable Investigational Product Of An Expanded Population Of Stem Cells At Umbilical Cord Blood Symposium In Israel
Source: Blood / Hematology News From Medical News Today [2009.11.03]
At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed participants on the current challenges presented by bone marrow transplantation and the importance of investigating cord blood as an alternative source for treating patients with leukemia and lymphoma.
Avoiding Infertility And Cancer With New Therapy For Vasculitis
Source: Fertility News From Medical News Today [2009.10.19]
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. The news was presented October 18 at the annual meeting of the American College of Rheumatology in Philadelphia.
Discovery Reveals Gene Activity Networks That Let Tumors Thrive And Suggests New Modes Of Therapy
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.14]
Researchers from Cold Spring Harbor Laboratory (CSHL) have uncovered a large, new cache of genes that act as built-in barriers against cancer. Known as tumor suppressors, the newly identified genes and the insight that they provide into devising new therapeutic strategies against lymphoma are described in a paper published in Cancer Cell. The CSHL team's discovery stems from their use of a powerful technology called RNA interference (RNAi), which suppresses gene activity.
|
